stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Free cash flow
Ionis Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was −$325.7M, compared with −$551.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$567.5M. Over the past ten years it has ranged from −$551.3M (fiscal 2024) to $585.3M (fiscal 2018); the current reading is higher than 27% of that period. Ionis Pharmaceuticals, Inc. ranks 596th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$325.7M | — |
| FY2024 | −$551.3M | — |
| FY2023 | −$335.5M | — |
| FY2022 | −$40.4M | — |
| FY2021 | $12.9M | — |
| FY2020 | −$5.2M | — |
| FY2019 | $309.3M | (47.14%) |
| FY2018 | $585.3M | 329.41% |
| FY2017 | $136.3M | — |
| FY2016 | −$123.6M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $547.3M | — |
| Mar 2026 | −$816.1M | — |
| Dec 2025 | −$160.4M | — |
| Sep 2025 | −$138.4M | — |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $79.8M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.6M |
| AXSM Axsome Therapeutics, Inc. compare | −$82.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$101.2M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| CGON CG Oncology, Inc. compare | −$179.3M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$308.9M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. | −$567.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement